sameAs
P112
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersMilnacipran: a unique antidepressant?The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise AlgorithmThe International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelinesThe International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future ResearchThe International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of GuidelinesMaking Sense of: Sensitization in SchizophreniaSevere depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatineWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disordersPosition statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depressionNeurobiological and clinical effects of the antidepressant tianeptineEfficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertralineAgomelatine in the treatment of seasonal affective disorderA pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertralineComparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial resultsPharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administrationThe relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practicePrinciples of practice from the European expert panel on the contemporary treatment of schizophrenia.A time of opportunity in schizophrenia.The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disordersA multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinitiesHow well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.[Tourette's syndrome - a review]Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials.Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla.Voxel-based morphometry at ultra-high fields. a comparison of 7T and 3T MRI dataConsensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials.Different fatal toxicity of neuroleptics identified by autopsy.Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].Social anxiety disorder: epidemiology, biology and treatment.Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression.First-episode schizophrenia: the importance of early intervention and subjective tolerability.Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.Monoamine depletion in non-pharmacological treatments for depression.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Prevention of seasonal affective disorder in daily clinical practice: results of a survey in German-speaking countriesSocial functioning in depression: a review.Additive gene-environment effects on hippocampal structure in healthy humans.Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment.
P50
Q22305681-602E250D-96A1-4F83-8098-55AE07967484Q24610271-DBAFC516-9505-4E19-9C37-42BA2D5AE7A2Q28066714-BFB08D77-93B9-46CF-9D04-6A738D1336B4Q28069743-55E06013-E1B5-4D8F-91F1-07482A0044EBQ28072601-53F156C2-85CE-46CA-AB06-B21BE2047505Q28076486-22DE2E71-F673-4804-BE07-F646FA841A37Q28077939-EA9E35FD-2E14-4596-86E5-45C3144C4CDCQ28240140-E686215C-4E63-41BD-9435-57CA21B76E38Q28249390-01196FB4-95F3-4050-BAA2-45A251FFE543Q28254016-CDDA39D6-4603-47C1-8556-0C81A14B01B3Q28260673-D63CE434-30D8-4FA9-B04A-054683C4BE24Q28274642-49E7D477-005D-4444-8078-8BCE8AF91F08Q28279108-E7F78675-787A-4056-8ACD-00CEEC7F6F3CQ28286878-C1AE5993-7E21-45B1-B786-7D771BFF14DFQ28297092-CE3689EC-8F0C-44F4-87FC-A3032DCCB5C8Q28374454-A9008624-536E-460A-A8D9-50EC1A44E3BEQ30251737-AF469AB4-1831-451A-8C51-54D8498FE245Q30363590-7E86ABC8-4005-4891-9C3E-D6AD6CCA2BF0Q30363592-7103C191-3505-4EF0-9F92-C4ADE9C751E6Q30583384-5104877C-C778-4F9D-BEC1-D46B817ECD30Q30583384-56E417D4-F09D-44FE-946C-AC1B8358A704Q30657759-F849ADE3-AB70-4D22-B13B-04B9406517DBQ30704426-2569322B-D0AF-4E9E-961F-C7CBE29F777CQ30720375-CED682AE-AC11-4ECA-9E64-AD6F551E52FCQ30746155-8E1A8820-8122-457D-AE80-FFD4BE73A04FQ30806116-89000FC7-FA5A-44E0-B1F8-136FA162CAAEQ30912675-DBFF0315-297A-401B-ADE3-739D480281E7Q31108616-AEEB1FA5-66F7-4955-A4FF-78F893951D13Q31140235-61CCFF88-4D8E-49EB-B3E0-29B8B6D43349Q33181922-CBE59702-6D93-4712-8DB0-3F6CB0C2CF09Q33247780-E3F01DA2-B9EF-4351-9BF8-AA8B86CA35F3Q33516535-669361D7-A11A-4445-9533-4A470D8B8283Q33612594-6EC95CC6-045B-4F57-8A00-1F20EDE0B683Q33810959-938B2AFB-6EA1-4D2F-8F72-4E2CAA825100Q33827648-5E4CFD7B-462C-418F-A922-BD347FD23FD0Q33865235-09E3CB69-3CD8-4840-9949-B87E0F26F53CQ33870389-4702B358-81FE-4A52-94FD-65BE39132848Q33892063-2A0D3A16-29B0-46CD-85EC-7F87CE6A75B7Q33929486-1113BB99-11EF-4755-8BA3-B4208EB76370Q33935999-6F99FE9E-4121-42F6-A21D-C01E880B2329
P50
description
Austrian psychiatrist
@en
Austrian psychiatrist
@en-ca
Austrian psychiatrist
@en-gb
aŭstra psikiatro
@eo
psiciatriste osteraices
@lfn
psiquiatra austríaco
@es
psychiater uit Oostenrijk
@nl
síciatraí Ostarach
@ga
österreichischer Psychiater und Hochschullehrer
@de
طبيب نفسي نمساوي
@ar
name
Siegfried Kasper
@ast
Siegfried Kasper
@ca
Siegfried Kasper
@da
Siegfried Kasper
@de
Siegfried Kasper
@en
Siegfried Kasper
@es
Siegfried Kasper
@fr
Siegfried Kasper
@ga
Siegfried Kasper
@nb
Siegfried Kasper
@nl
type
label
Siegfried Kasper
@ast
Siegfried Kasper
@ca
Siegfried Kasper
@da
Siegfried Kasper
@de
Siegfried Kasper
@en
Siegfried Kasper
@es
Siegfried Kasper
@fr
Siegfried Kasper
@ga
Siegfried Kasper
@nb
Siegfried Kasper
@nl
altLabel
S Kasper
@en
S. Kasper
@en
Siegfried F Kasper
@en
Siegfried F. Kasper
@en
prefLabel
Siegfried Kasper
@ast
Siegfried Kasper
@ca
Siegfried Kasper
@da
Siegfried Kasper
@de
Siegfried Kasper
@en
Siegfried Kasper
@es
Siegfried Kasper
@fr
Siegfried Kasper
@ga
Siegfried Kasper
@nb
Siegfried Kasper
@nl